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Postoperative acute kidney injury (po-AKI) is frequently observed after major vascular sur-
gery and impacts on mortality rates. Early identification of po-AKI patients using the novel
urinary biomarkers insulin-like growth factor-binding-protein 7 (IGFBP7) and tissue inhibitor
of metalloproteinases-2 (TIMP-2) might help in early identification of individuals at risk of
AKI and enable timely introduction of preventative or therapeutic interventions with the aim
of reducing the incidence of po-AKI. We investigated whether biomarker-based monitoring
would allow for early detection of po-AKI in patients undergoing abdominal aortic
interventions.
Methods
In an investigator-initiated prospective single-center observational study in a tertiary care
academic center, adult patients with emergency/ elective abdominal aortic repair were
included. Patients were tested for concentrations of urinary (TIMP-2) x (IGFBP7) at baseline,
after surgical interventions (PO), and in the mornings of the first postoperative day (POD1).
The primary endpoint was a difference in urinary (TIMP-2) x (IGFBP7) levels at POD1 in
patients with/ without po-AKI (all KDIGO stages, po-AKI until seven days after surgery). Sec-
ondary endpoints included sensitivity/ specificity analyses of previously proposed cut-off lev-
els and clinical outcome measures (e.g. need for renal replacement therapy).
Results
93 patients (n = 71 open surgery) were included. Po-AKI was observed in 33% (31/93) of
patients. Urinary (TIMP-2) x (IGFBP7) levels at POD1 did not differ between patients with/
without AKI (median 0.39, interquartile range [IQR] 0.13–1.05 and median 0.23, IQR 0.14–
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0.53, p = .11, respectively) and PO (median 0.2, IQR 0.08–0.42, 0.18, IQR 0.09–0.46; p =
.79). Higher median (TIMP-2) x (IGFBP7) levels were noted in KDIGO stage 3 pAKI patients
at POD1 (3.75, IQR 1.97–6.92; p = .003). Previously proposed cutoff levels (0.3, 2) showed
moderate sensitivity/ specificity (0.58/0.58 and 0.16/0.98, respectively).
Conclusion
In a prospective monocentric observational study in patients after abdominal aortic repair,
early assessment of urinary (TIMP-2) x (IGFBP7) did not appear to have adequate sensitiv-
ity/ specificity to identify patients that later developed postoperative AKI.
Clinicaltrials.gov
NCT03469765, registered March 19, 2018.
Introduction
Post-operative acute kidney injury (po-AKI) is often observed after cardiovascular surgery and
negatively impacts on both morbidity and mortality rates [1]. AKI incidence in open abdomi-
nal aortic repair is reported to range from 20–37% [2], and increases to about 68% and 75% in
suprarenal aortic aneurysm repair and ruptured aortic aneurysms, respectively [3]. In endo-
vascular aortic repair (EVAR), AKI is noted in 9–18% of cases [3,4].
Post-operative renal (dys)-function is influenced by several factors including pre-operative
renal function, co-morbidities, intraoperative factors (e.g. aortic clamping site and time, ische-
mia-reperfusion injury), hemodynamic instability (including vasopressor use, blood loss and
need for volume replacement) and post-operative complications [5–8]. As no (or controver-
sial) evidence for perioperative pharmacological measures to prevent po-AKI (e.g. mannitol,
fenoldopam) exists [9–11], early recognition of po-AKI seems pivotal. Currently, po-AKI diag-
nosis is based on assessment of (course of) serum creatinine and thus estimated glomerular fil-
tration rate (eGFR), and/or urinary output. However, respective indices may be considered
insensitive in regard to timely po-AKI recognition [12].
Recently, new biomarkers including insulin-like growth factor binding protein 7
(IGFBP7) and tissue-inhibitor of metalloproteinases-2 (TIMP-2) were proposed for early
detection of AKI [13]. Respective markers are considered cell cycle arrest markers and
viewed to represent “renal stress”, rather than established renal damage [12]. In human kid-
neys, TIMP-2 is expressed in the distal nephron, whereas IGFBP7-expression is observed
predominantly in the proximal tubule [14] with both markers detectable in urinary samples
[12]. Both biomarkers are determined together as they showed additive value in a discovery
study [13]. Moreover, both are released after a variety of possible renal insults (among others
inflammation, toxins, drugs, and/or oxidative stress) [13] resulting in a potential application
irrespective of underlying AKI pathology [15,16]. Data from patients with decompensated
heart failure [17], major non-cardiac surgery patients [18,19], and critically ill patients
[20,21] demonstrate good accuracy in predicting AKI. However, in patients undergoing car-
diac surgery, data is contradictory [22–26] with a recent meta-analysis underlining the need
for subsequent investigations [15]. A cut-off threshold of (TIMP-2) x (IGFBP7) <0.3 is pro-
posed as low risk for po-AKI development, whereas patients with levels of >0.3 and <2 are
regarded to have moderate AKI risk. (TIMP-2) x (IGFBP7) values >2 were previously pro-
posed to be associated with a high risk for po-AKI development [16]. However, further
research seems required before biomarker-based strategies can be implemented into clinical
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practice as e.g. specificity of investigated patient cohorts, potential co-medications, and
other factors could affect sensitivity and specificity [27,28].
Currently, data on biomarkers for timely prediction of postoperative renal outcomes are
not available for open abdominal aortic repair and EVAR patients. We therefore performed an
investigator-initiated prospective observational study to investigate whether early assessment
of the biomarker (TIMP-2) x (IGFBP7) would predict po-AKI in patients with abdominal aor-
tic repair.
Materials and methods
Study characteristics and study patients
The (Timp-2) x (IGfbp7) as early renal biomarker for the prediction of acute kidney injury in
aortic surgery (TIGER) study was an investigator-initiated, single center, prospective, observa-
tional study. Patients with emergency or elective abdominal aortic surgery (open repair with
infra- or suprarenal clamping, or EVAR) referred to our university-based cardiovascular cen-
ter were eligible for study inclusion. The study was performed from June 2018 to September
2019. Patients were excluded if any of the following criteria were met: 1) patient unable to pro-
vide informed consent (e.g. due to pre-existing severe neurological or psychiatric illness) or
institutionalized patients, 2) Age< 18 years and/or 3) patients not speaking German or
French. Besides additional biomarker monitoring, all patients received best standard-of-care
treatment according to local standard operating procedures (SOP) without interference by the
research team. The study was approved by the local Ethics Committee on Human Research
(Kantonale Ethikkomission, KEK, Bern, Nr. 2018–00331). Written informed consent was
obtained from all patients or respective representatives. The study was registered on Clinical-
trials.gov (NCT 03469765, registered March 19, 2018). Data quality visits (in-/exlusion criteria,
informed consent, primary endpoint data) were performed by an internal qualified person.
Study endpoints
The primary endpoint of the study was defined as a statistical significant difference in total
(TIMP-2) x (IGFBP7) levels at the first postoperative day (POD1) in patients without/ with
po-AKI developed in the first seven days after surgery (defined along Kidney Disease: Improv-
ing Global Outcomes (KDIGO) definitions, stages 1–3 [29]).
Secondary endpoints included A) sensitivity/specificity analyses of (TIMP-2) x (IGFBP7)
along KDIGO-categories, B) comparison of the area under receiver operating characteristic
curves (AUROC) for: (TIMP-2) x (IGFBP7), fractional excretion of sodium (FeNa), C)
descriptive analysis of clinical endpoints including number of patients on renal replacement
therapy (RRT), intensive care unit (ICU) length of stay, intermediate care unit (IMC) length
of stay, hospital length of stay (LOS), and ICU-, hospital-, and 28-day-mortality. Subgroup-
analyses were performed for type of surgery (open surgery, emergency and/or planned sur-
gery). Further, the diagnostic value of absolute (Δ(TIMP-2) x (IGFBP7) 1st POD = (TIMP-2)
x (IGFBP7) 1st POD—(TIMP-2) x (IGFBP7) baseline) and relative change (Δ (TIMP-2) x
(IGFBP7) 1st POD [%] = [100/(TIMP-2) x (IGFBP7) baseline] � Δ (TIMP-2) x (IGFBP7) 1st
POD) in urinary (TIMP-2) x (IGFBP7) was estimated.
Biomarker assessment and patient data
Urinary and blood samples were obtained after anesthesia induction (baseline), after end of
anesthesia (before IMC/ICU-admission, PO), and in the morning of the day after surgery
(minimum of 8 hours up to 24 hours post-operatively, POD1). Urinary concentrations of
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TIMP-2 and IGFBP7 were measured using a commercially available standardized assay
(NephroCheck, Astute Medical, San Diego, CA, USA). Test results are given as product of
both markers in (ng/ml)2/ 1000. Blood and urinary creatinine and sodium concentrations
were assessed to calculate fractional sodium excretion. Other post-operative laboratory param-
eters were assessed at the discretion of the independent treating physician.
The following pre-operative data were recorded: age; sex; BMI; American Society of Anes-
thesiologists (ASA) physical status classification system; comorbidities and routine medica-
tions. Laboratory parameters including serum creatinine, urea, sodium, eGFR (Chronic
Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) [30]. Diagnostic procedures
using contrast agents (if applicable) were recorded in the 24 hours proceeding operations. The
following perioperative data were recorded: type of surgery (infra- vs. suprarenal clamping,
EVAR and emergency vs. elective); duration of clamping (if applicable); use/ duration of cold
renal perfusion; use/ quantity of contrast agents (if applicable); duration of surgery; episodes
of hypotension (mean arterial blood pressure < 20% of baseline for more than 5 minutes);
cumulative dose/ type of fluids applied including autologous and allogenic packed red blood
cells (RBC), fresh frozen plasma (FFP), and platelet transfusions; blood loss; use/ dose of
mannitol; use/ cumulative dose of vasopressors or inotropes, and urine output during surgery.
Data recorded post-operatively included routine laboratory parameters until hospital dis-
charge (if available: sodium, potassium, serum creatinine, urea, eGFR, hemoglobin); cumula-
tive urinary output while on IMC/ ICU; clinically overt complications after surgery (sepsis,
colon ischemia, wound infection, pneumonia, delirium, others); need for and duration of
RRT; length-of stay in IMC and/or ICU, length of hospital stay. ICU-/IMC-, in-hospital- and
28-day- mortality was recorded.
Sample size calculation
An incidence of 20% po-AKI was expected in the cohort under investigation. Based on
(TIMP-2) x (IGFBP7) data of previous studies in cardiac surgery patients [22,26], we assumed
to reach a mean (TIMP-2) x (IGFBP7) in patients without AKI of 0.4 (ng/ml)2/ 1000 and in
patients with AKI (i.e. KDIGO stages 1–3) a mean of 1.6 (ng/ml)2/ 1000 with a standard devia-
tion (SD) of 1.4. If the true difference in the experimental and control means is 1.2, n = 18
experimental subjects and 72 control subjects are required to reject the null hypothesis that the
population means of the experimental and control groups are equal with a probability (power)
of 0.9. The Type I error probability associated with this test of this null hypothesis is 0.05.
Assuming a drop-out rate greater than 10%, a total of 100 patients are intended to be included.
Statistical analysis
For statistical analysis, Student’s t-test for normally distributed data and the Mann–Whitney U
test for non-normally distributed data was used to compare quantitative variables between
groups, ANOVA for multiple groups. Chi square test or Fisher’s exact test were used for quali-
tative variables, as appropriate. Statistical significance was assumed for p<0.05. Sensitivity-/
specificity-analysis were performed using receiver-operating characteristics (ROC) curves
using the R software package cutpointr. Diagnostic value of a biomarker is defined as excellent
with Area Under the Receiver Operating Characteristics curve (AUROC) >0.9, as good with
a AUROC between 0.75–0.9, as poor with a AUROC between 0.50–0.75 and as without any
diagnostic value with AUROC values <0.5 [31]. Optimal cut-off values were estimated using
the Youden index [31]. No optimal cut-off point was calculated for curves with poor or lower
diagnostic value and for exploratory analyses. All statistical analyses were performed using the
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softwares SPSS for Windows (version 25;SPSS Inc., Chicago, IL, USA) and R, version 3.6.1,
and Rstudio version 1.2.5001.
Results
Patient demographics
One hundred-thirty seven patients were screened for study participation, with 100 patients eli-
gible for study inclusion (Fig 1). Ninety-three patients were included in the final analysis set
(n = 7 dropouts due to incomplete specimen sampling). As defined by KDIGO criteria, po-
AKI was observed in 31 of 93 patients (33.3%) with n = 20, n = 6, n = 5 patients in KDIGO
stages 1, 2, and 3, respectively. Po-AKI was diagnosed based on increased serum creatinine
(n = 18), on reduced urinary output (n = 1), and based on both parameters (n = 12). Baseline
demographics (Table 1) and intra-operative patient characteristics (Table 2) are given. Patients
with po-AKI had higher pre-operative (104.4 ± 50.1 vs. 83.9 ± 27.4 μmol/l; p = .02) creatinine
levels (Table 1). AKI patients more often had open rather than endovascular procedures, more
often emergency rather than elective surgery, had longer duration of surgery, more supra- or
intrarenal clamping, and received more often cold renal perfusion (all p< .05) (Table 2). Num-
bers of hypotensive episodes were increased in the po-AKI-group (44.3 ± 25.8 vs.27.7 ± 20.2; p
= .001) despite more frequent use of vasopressors (norepinephrine) (96.8% vs. 80.6%; p = .03).
Po-AKI was further associated with higher transfusion rates for autologous (87.1% vs 62.9%; p
= .02) and allogeneic red blood cells (48.4% vs. 11.3%; p = .001) and fresh frozen plasma
(FFPs) (45.2% vs 17.7%; p = .005). No differences were noted regarding intraoperative blood
loss (p = .10) (Table 2).
Fig 1. Patient flow chart. RRT Renal Replacement Therapy; IC informed consent; EVAR endovascular aortic repair.
https://doi.org/10.1371/journal.pone.0244658.g001
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(TIMP-2) x (IGFBP7) and AKI diagnosis
Measurement of urinary (TIMP-2) x (IGFBP7) on the morning of the first postoperative day
(POD1, primary endpoint) was performed on average at 14.4 hours (± 4.3 hours) after end
of surgery. No statistically significant differences were noted with regard to (TIMP-2) x
(IGFBP7) levels of patients with/ without AKI on both POD1 and immediately after surgery
(Table 3, S1 Fig). The AUROC-value of urinary (TIMP-2)x (IGFBP7) for POD1 assessments
was 0.6 (95%-CI 0.49–0.71) and 0.52 (95%-CI 0.41–0.62) for the postoperative (PO) measure-
ment (Fig 2). Applying the previously proposed cut-off levels of 0.3 and 2.0 to our results
returned in sensitivities/specificities of 0.58/0.58 and 0.16/0.98, respectively. Negative predic-
tive values (NPV) were 0.76 and 0.84 for testing at POD1 (for the proposed cutoffs of 0.3
and 2, respectively). For PO measurements, the previously proposed cut-offs of 0.3 and 2.0
returned in sensitivities/ specificities of 0.32/ 0.6 and 0.1/0.97, respectively (NPV 0.667 and
0.9). By using the Youden-Index we determined the following optimal cutoffs for urinary
(TIMP-2) x (IGFBP7) at POD1: 0.43 (95%-CI 0.22–2.42) (sensitivity 0.45, specificity 0.65). As
AUROC of urinary (TIMP-2) x (IGFBP7) was low for the immediate post-operative biomarker
sample, optimal cutoffs were not tested.
Table 1. Baseline demographics and variables.
Total (n = 93) AKI group (n = 31) No AKI group (n = 62) p-value
Age 69.4 ± 9.9 71.3 ± 9.8 68.5 ± 9.9 .34
Gender (male) 77 (82.8%) 23(74.2%) 54 (87.1%) .12
BMI 26.6 ± 4.4 27.4 ± 4.7 26.2 ± 4.3 .06
Preoperative Crea� 87 (74.25;100.75) 93 (82;122) 84 (71.5;98) .03
Preoperative eGFR� 75.5 (62.25;89) 67(49;84) 81(64;90) .02
Hb preoperative� 139.5 122.25;146) 130(116;146) 141(126.5;146.5) .12
CAD 41 (44.1%) 13 (41.9%) 28 (45.2%) .77
HF >NYHA 1 14 (15.1%) 5 (16.1%) 9 (14.5%) .84
Liver Cirrhosis 2 (2.2%) 0 2(2.2%) .31
Diabetes 15 (16.1%) 4 (12.9%) 11 (17.7%) .55
CKD 27 (29%) 13 (41.9%) 14 (22.6%) .05
Hypertension 71 (76.3%) 26 (83.9%) 45 (72.6%) .23
COPD 22 (23.7%) 11 (35.5%) 11 (17.7%) .06
ASA class .11
2 4 0 4
3 50 13 37
4 35 16 19
5 4 2 2
Reason for Surgery .51
Aortic Aneurysm 77 (82.8%) 26(82.9%) 51 (82.3%)
aorto-iliac occlusive disease 11 (11.8%) 3 (9.7%) 8 (12.9%)
Graft infection 1 (1.1%) 1(3.2%) 0
Other 4 (4.3%) 1 (3.2%) 3(4.3%)
CM in 24h preoperative 15(16.1%) 8 (25.8%) 7 (11.3%) .07
Means and standard deviations (SD), medians and interquartile range (IQR) or total numbers (percentages) are given. Crea (serum) creatinine; eGFR estimated
glomerular filtration rate; Hb hemoglobin; CAD coronary artery disease; COPD chronic obstructive pulmonary disease; CKD chronic kidney disease; HF heart failure;
NYHA New York Heart Association Classification; ACE-I Angiotensin converting enzyme inhibitor; ARB Angiotensin II receptor blocker; BB Beta blocker; ASA
American Society of Anesthesiologists physical status classification system; CM contrast media;
� n = 92 due to 1 missing value.
https://doi.org/10.1371/journal.pone.0244658.t001
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Additionally, when Δ (TIMP-2) x (IGFBP7) (i.e. POD1 vs. baseline) was investigated, an
AUROC of 0.63 (95%CI 0.52–0.72) for absolute and 0.65 (95%CI 0.56–0.62) for relative values
of urinary (TIMP-2) x (IGFBP7) was noted.
Clinical outcomes and fractional excretion of sodium (FeNa)
In patients with po-AKI, an early post-operative increase in serum creatinine levels after sur-
gery was observed. No differences were noted in regard to early fractional sodium excretions
Table 2. Intraoperative patient characteristics.
Total (n = 93) AKI group (n = 31) No AKI group (n = 62) p-value
Type of Surgery .03
Open surgery 71 (76.3%) 28 (90.3%) 43 (69.4%)
EVAR 22 (23.7%) 3(9.7%) 19 (30.6%)
Re-Surgery 10 (10.8%) 4 (12.9%) 6 (9.7%) .64
Urgency of surgery .02
Elective 78 (83.9%) 22 (71%) 56 (90.3%)
Emergency 15 (16.1%) 9 (29%) 6 (9.7%)
Type of anesthesia .03
GA only 24 (25.8%) 13 (41.9%) 11 (17.7%)
Combined (GA + PDA) 56 (60.2%) 17 (54.8%) 39 (62.9%)
Regional only 4 (4.3%) 0 4 (6.5%)
LA MAC 9 (9.7%) 1 (3.2%) 8 (12.9%)
Duration of surgery (min) 293 ± 156.6 369 ± 182.2 254.9 ± 127.5 .004
Type of clamping .01
None 22 (23.7%) 3 (9.7%) 19 (30.6%)
Suprarenal 31 (33.3%) 17 (54.8%) 14 (22.6%)
Intrarenal 2 (2.2%) 1 (3.2%) 1 (1.6%)
Infrarenal 38 (40.9%) 10 (32.3%) 28 (45.2%)
Duration of total aortic clamp (min) 81.2 ± 36.5 87.4 ± 42.3 77.2 ± 32 .23
Cold renal perfusion 7 (7.5%) 5 (16.1%) 2 (3.2%) .03
Number of hypotensive episodes (systolic BP�20% of baseline for 5 min.) 33.3 ± 23.4 44.3 ± 25.8 27.7 ± 20.2 .001
Blood loss (ml)� 1950 (1550;4375) 2400 (1550;4375) 1950 (1000;2775) .10
Urinary output �� 520 (268;820) 590 (268;820) 520 (198;1033) .58
Mannitol intraoperative 43(46.2%) 18 (58.1%) 25 (40.3%) .11
NA intraoperative 80 (86%) 30 (96.8%) 50 (80.6%) .03
NA cumulative dose (μg) 908 (515;1415) 1068 (596;1592) 745 (402;1257) .05
Ringer Lactate given 5697.3±3820.2 6877.4±4249.5 5107.3±3473.9 .05
Autologous RBC given 66 (71%) 27 (87.1%) 39 (62.9%) .02
Vol. of autologous RBC (ml) 964 (630;170) 1320 (744;1929) 880 (600;1290) .08
Allogenic RBC given 22 (23.7%) 15 (48.4%) 7 (11.3%) <.0001
Vol. of allogenic RBC (ml) 1200 (550;1788) 1375 (825;2200) 550 (275;1650) .24
FFP intraoperative 25 (26.9%) 14 (45.2%) 11 (17.7%) .005
Vol. of FFP (ml) 1000 (500;2250) 1125 (500;2500) 750 (500;1500) .4
Means and SD, medians and interquartile range or total numbers (percentages) are given. EVAR endovascular aortic repair; GA general anesthesia; PDA epidural
anesthesia; LA MAC local anesthesia, monitored anesthesia care; BP blood pressure; NA Noradrenalin; RBC red blood cell concentrate; FFP fresh frozen plasma; Vol.
volume.
� n = 80 due to 13 missing values,
��n = 84 due to 9 missing values.
https://doi.org/10.1371/journal.pone.0244658.t002
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between patients with vs. without AKI (Table 3). AUROC for FeNa-values immediately after
surgery and on POD1 were 0.57 (95%CI 0.47–0.66) and 0.47 (95%CI 0.37–0.57), respectively.
One (3.2%) patient died in the AKI group (Table 3). Three (10%) patients required RRT
postoperatively, with one (3.2%) patient in need for RRT at day 28. Longer ICU-, IMC-, and
hospital stay was noted in patients with AKI (all p< .05) (Table 3). Increased rates of clinically
overt postsurgical complications were noted in the AKI group (71% vs 26% without AKI; p<
.0001) (Table 3).
Table 3. Primary and secondary endpoints in AKI vs. non-AKI groups.
Total (n = 93) AKI group (n = 31) No AKI group (n = 62) p-value
Primary Endpoint
(TIMP-2)x(IGFBP7) at POD1 0.39(0.13;1.05) 0.02–8.71 0.23(0.14;0.53) 0.03–2.0 .11
Secondary Endpoints
(TIMP2)x(IGFBP7) at PO 0.2(0.08;0.42) 0.03–6.28 0.18(0.09; 0.46) 0.02–6 .79
FeNa PO (%) 1.21 (0.68;2.1) 0.17–10.19 0.996 (0.58;1.83) 0.07–7.48 .30
FeNa at POD1 (%) 0.58 (0.26;1.16) 0.07–3.29 0.61(0.22;1.01) 0.01–4.41 .65
LOS ICU/ IMC 0.93 (0.79;1.86) 2.02–117.38 1.78 (0.78;4.3) 0.36–21.8 0.9 (0.79;1.8) 0.03–4.78 .003
LOS Hospital 8.96(7.02;12.02) 2.02–117.38 12.02(9.01;22.79) 3.15–117.38 7.97(3.99;9.7) 2.02–40.46) <.0001
Need for RRT 3 (3.3%) 3 (10%) 0
Need for RRT on day 28 1 (1.1%) 1 (3.2%) 0
Clinically overt complications 38 (41.3%) 22 (71%) 16 (25.8%) <.0001
Sepsis 2 0
Colon ischemia 1 0
Wound infection 1 3
Pneumonia 1 1
Delirium 2 1
Others and/or multiple 17 11
ICU Mortality 1 (1.1%) 1(3.2%) 0 .16
Hospital Mortality 1 (1.1%) 1(3.2%) 0 .16
Means and SDs and/or medians (interquartile ranges) and ranges are given, as appropriate. POD1 first post-operative day; PO postoperative; Crea (serum) creatinine;
postop post-operative; FeNa fractional excretion of sodium; Hb hemoglobin; ICU intensive care unit; IMC intermediate care unit; LOS Length of stay; (TIMP2) x
(IGFBP7) tissue inhibitor of metalloproteinases-2 × insulin-like growth factor binding protein-7.
https://doi.org/10.1371/journal.pone.0244658.t003
Fig 2. Receiver operating characteristic (ROC) curves of urinary (TIMP-2)x(IGFBP7). (A)post-operative (PO) and
(B) first post-operative day (POD1) samples.
https://doi.org/10.1371/journal.pone.0244658.g002
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(TIMP-2) x (IGFBP7) levels along KDIGO AKI stages
Along KDIGO AKI stages, we observed a statistically significant difference with an increased
(TIMP-2) x (IGFBP7) levels in KDIGO AKI stage 3 at POD1 only (p = .003) (Table 4).
AUROC showed good diagnostic value for diagnosis of KDIGO AKI stage 3 (AUC 0.98, 95%
CI 0.97–1) at POD1, but estimation based on a limited number of samples (n = 5) (indicating
high risk of bias, S2 Fig). Combination of po-AKI stages 2 and 3 (as analyzed previously
[13,19]) did not change the discriminatory power of the analysis (no statistical significant dif-
ferences in (TIMP-2) x (IGFBP7) values of patients with (AKI stages 2+3)/ without (AKI stages
0+1) AKI on POD1 (median 0.39 vs 0.26, p = .05) (S3 Fig).
(TIMP-2) x (IGFBP7) levels: Open surgical procedures
Seventy-one patients (76.3% of total population) received open surgery, out of which n = 28
(39.4%) had post-operative AKI (n = 18, n = 5, and n = 5 at KDIGO stages 1, 2, and 3, respec-
tively). (TIMP-2) x (IGFBP7) levels did not differ statistically between patients with vs. without
AKI immediately after the operation and at POD1 (all p>.05). Along the KDIGO stages, we
observed a significant different distribution of (TIMP-2) x (IGFBP7) values with lower levels
in AKI stages 0, 1, and 2 at PO (p = .04) with higher levels in KDIGO AKI stage 3 at POD1 (p
= .004). Due to limited sample size, we refrained from a formal sensitivity/specificity analysis
in patients with KDIGO AKI stages 2 and 3.
(TIMP-2) x (IGFBP7) levels: Scheduled and emergency procedures
Seventy-eight patients received scheduled procedures (22 EVAR, 56 open surgery) out of
which n = 22 (31%) had post-operative AKI (n = 16, n = 5, n = 1 at KDIGO stages 1, 2, and 3,
respectively). No significant differences in median (TIMP-2) x (IGFBP7) levels were observed
for patients with vs. without AKI (KDIGO classification) at PO and POD1 (all p>.05). Fifteen
patients underwent emergency aortic surgery with po-AKI diagnosed in 9 (60%) of cases
(n = 4, n = 1, and n = 4 at KDIGO stages 1, 2, and 3, respectively). In this subgroup with a lim-
ited sample size, (TIMP-2) x (IGFBP7) levels differed between patients with vs. without AKI at
POD1 (p = .02) without differences at PO (p = .28). Due to limited sample size, a formal sensi-
tivity/ specificity analysis was refrained from.
Discussion
In an investigator-initiated prospective monocentric observational study, we did not observe
differences in early postoperative (TIMP-2) x (IGFBP7) levels in abdominal aortic surgery
Table 4. Comparison of (TIMP-2) x (IGFBP7) along KDIGO AKI stages.
KDIGO AKI stages
No AKI Stage 1 Stage 2 Stage 3 p
N 62 20 6 5
Baseline 0.66 (0.32;1.2) 0.53 (0.2;1.11) 0.6 (0.14;1.7) 0.16 (0.14;1.06) 0.28
0.02–4.07 0.02–1.42 0.05–4.2 0.13–1.95
Postoperative (PO) 0.18 (0.09;046) 0.205 (0.09;0.42) 0.08 (0.078;0.18) 0.66 (0.24;1.83) 0.09
0.02–6 0.04–6.28 0.03–0.42 0.2–2.12
1st postop day (POD) 0.23 (0.14;0.53) 0.35 (0.1; 0.8) 0.27 (0.11; 0.38) 3.75 (1.97;6.92) 0.003
0.03–2 0.02–2.86 0.04–0.39 1.51–8.71
Presented are medians (interquartile ranges) and ranges.
https://doi.org/10.1371/journal.pone.0244658.t004
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patients with versus without po-AKI which developed in the first seven days after surgery.
Higher median (TIMP-2) x (IGFBP7) levels were noted in cases of severe AKI (KDIGO stage
3). These findings were consistent along the investigated subgroups. Our findings are in con-
trast to previous studies demonstrating good accuracy in prediction of all-stage AKI [18,22] or
KDIGO-AKI-stages 2 and 3 [13,18,19,24]. However, other authors showed that (TIMP-2) x
(IGFBP7) may distinguish between patients with vs. without AKI, but with limited diagnostic
accuracy following cardiac surgery [25,26].
We deliberately aimed to investigate (TIMP-2) x (IGFBP7) in patients undergoing abdomi-
nal aortic procedures as this patient group is considered at particular high risk for post-opera-
tive AKI [3]. Therefore, our patient cohort may include some heterogeneity with regard to the
surgical intervention chosen (open vs. endovascular repair, emergency vs. scheduled proce-
dures) and po-AKI etiology (inflammation, ischemia-reperfusion injury, [micro-]embolization,
contrast media application, hemodynamic perturbations, and others). However, the recent lit-
erature suggests that the biomarker under investigation reflects “renal stress” induced following
various renal injuries (inflammation, toxins, drugs, oxidative stress) [12]. Others have previ-
ously tested TIMP2xIGFBP7 in a variety of pathologies leading to AKI including e.g. cardiac
surgery, major non-cardiac surgery, transcatheter aortic valve implantation (TAVI), critical ill-
ness, heart failure and platinum-based chemotherapy and have showed rather consistent results
[17,18,20,22,23,32]. Thus, current recommendations suggest (TIMP-2) x (IGFBP7) testing in
different patient cohorts irrespective of po-AKI-etiology [16], as performed in this study.
The po-AKI incidence observed (33% in overall cohort, 39% in patients receiving open aor-
tic interventions) might be comparable to previous studies including cardiac and major non-
cardiac surgery [22,24]. Of note, the subgroup with moderate to severe AKI according KDIGO
(12% in our study) appeared rather comparable to other studies [22,26] or the rate is even
higher [24,25]. Further, demographics and course of respective patients (including length of
stay and number of postoperative complications) was also considered rather typical for AKI
patients.
Recommendations for (TIMP-2) x (IGFBP7) assessment vary regarding the time of assess-
ment [26]. We thus chose to measure (TIMP-2) x (IGFBP7) immediately after surgery and in
the morning of the first postoperative day. This was performed deliberately for pragmatic rea-
sons rather than artificial study conditions. On many if not most ICUs, respective markers
would be tested at the timepoints investigated. However, earlier studies in cardiac and non-
cardiac major surgery differed with regard to timing of (TIMP-2) x (IGFBP7) testing and
chosen time points ranged from intra-operative testing [24], to 0 to 6 hours post-operatively
[18,24–26], until post-operative day 3 [24]. Some authors tested urinary (TIMP-2) x (IGFBP7)
immediately after surgery and observed decreasing (TIMP-2) x (IGFBP7) values (when com-
pared to baseline) without differences in (TIMP-2) x (IGFBP7) levels between patients with vs.
without AKI [24,25], which is in line with our findings.
Earlier studies in healthy subjects and in patients with stable chronic comorbidities showed
a (TIMP-2) x (IGFBP7) reference intervals of 0.04 to 2.22 (ng/ml)2/ 1000 with a median at
about 0.3 (and 75%<0.75 (ng/ml)2/ 1000) [33]. One might thus argue whether the observed
increased baseline values in our study would reflect this range. Nevertheless, although we are
unable to conclude on the underlying mechanisms, respective baseline levels may theoretically
be related to pre-operative fasting. AKI stage 3 patients were mostly emergency patients and
might theoretically have been pre-hydrated to a larger extent.
Further, timing of (TIMP-2) x (IGFBP7) may be crucial. Measurements 4–6 hours after sur-
gery could be regarded the earliest time point for assessment [22,24]. In addition, underlying
intraoperative mechanisms for AKI may differ in cardiac and vascular surgery patients (e.g.
altered renal blood flow, inflammation, and haemolysis) [11], which could theoretically
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explain some of the differences between previous cardiac surgery studies and the current pre-
sented data. Nevertheless, in our study, the typical post-operative course of plasma creatinine
and/ or decline in urinary output at 12 and 24 hours post-operatively indicated most patients
with moderate to severe AKI within 14 hours. Further, 2 out of 3 patients received RRT within
24 hours. A theoretical “ideal” renal biomarker would likely diagnose moderate to severe AKI
early after the impact, with good discriminatory power superior or additive to established
renal biomarkers. In accordance with other studies [25,26], our data might thus challenge the
early use of urinary (TIMP-2) x (IGFBP7) in patients with abdominal aortic procedures. Previ-
ously, patients with negative urinary (TIMP-2) x (IGFBP7) (<0,3[ng/ml]2/1000) were pro-
posed as potential “fast track” patients [16]. Here, 50% of patients with KDIGO AKI stage 2
had levels <0.3. Thus, respective recommendations should likely be limited to cardiac surgery
patients in which more data is available. However, as course of creatinine and/or urinary out-
put indicated development of po-AKI in nearly all patients with in the first 14hours post-
surgery, we theoretically might have missed maximum TIMP2xIFGBP7 concentrations.
Therefore, further studies on biomarker kinetics such as the study of Cummings et al. [34]
seem warranted.
Our study has important further limitations that deserve discussion. First, even if ade-
quately powered (assumed vs. observed AKI incidence: 20% vs. 33%; assumed vs. observed
drop-out rate 10% vs. 7%) to detect a difference in patients with AKI according to all KDIGO
stages, the sample size of our study is limited and our results warrant larger confirmatory
investigations. Second, we present data from a monocentric study with all inherent limitations.
Third, pre-operative risk prediction and selection of patients (at higher risk) might have
(theoretically) influenced biomarker performance [22,35]. Fourth, we assessed (TIMP-2) x
(IGFBP7) at baseline and twice post-operatively. As kinetics appear not yet exactly understood,
exact timing may be crucial, and more measurements might have potentially revealed a larger
(temporary) rise in affected patients. Fifth, we did not test (TIMP-2) x (IGFBP7) in combina-
tion with other biomarkers e.g. urinary neutrophil gelatinase-associated lipocalin (NGAL) or
peak serum cystatin C. Combining several biomarkers may improve predictive power [36].
Sixth, building of ROC curves and estimating AUROC in the subgroup of KDIGO-AKI stage 3
patients was based on a limited number of study patients. However, we aimed to account for
this by bootstrapping with 1000 iterations. Seventh, in line with previous studies [22,26], this
study was designed to potentially predict AKI at any AKI stage, whereas the biomarker is only
validated to detect moderate to severe AKI [13].
Conclusions
In an investigator-initiated prospective monocentric observational study, we did not observe
differences in early postoperative (TIMP-2) x (IGFBP7) levels in abdominal aortic surgery
patients with versus without postoperative AKI that developed in the first seven days after sur-
gery. Subgroup analysis showed higher median (TIMP-2) x (IGFBP7) levels in patients with
severe postoperative AKI (KDIGO stage 3). Further studies are required regarding the specific
type of interventions and the kinetics of the biomarker.
Supporting information
S1 Fig. (TIMP2) x (IGFBP7) over time for patients with AKI/ without AKI (no AKI). Medi-
ans and IQRs are given.
(TIF)
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S2 Fig. ROC curves of urinary (TIMP-2)x(IGFBP7) according to KDIGO-AKI stages at the
first postoperative day (POD1). (A) stage 1 vs. all other stages, (B) stage 2 vs. all other stages,
(C) stage 3 vs. all other stages.
(TIF)
S3 Fig. Boxplots of the subgroups of AKI stages 0+1 versus AKI stages 2+3. n.s. p .05.
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